Brevets / Patents

2022. C. Beard, K. Bharucha, P. Bougneres (Adrenas Therapeutics), E. David, R. Eclov, R. Escandon, G. Laforet, A. Shaywitz. Gene therapies for 21-Hydroxylase deficiency. WO/2022/198038. https://data.inpi.fr/brevets/WO2022198038?q=#WO2022198038

2021. H M Puccio, P Aubourg, R. G. Crystal, P. Bougneres. Methods and pharmaceutical compositions for the treatment and the prevention of cardiomyopathy dur to energy failure. US20220090128. https://patentscope.wipo.int/search/en/detail.jsf?docId=US355368801&_cid=P20-LHRNJ8-31186-1

2020. L. Massade (inventeur principal), C. Massaad, S. Boutary, G. Urbinati, P. Couvreur, D. Desmaële. Antisense RNA targeting PMP22 for the treatment of CMT1A. International: WO2020064749; Europe n° 18306241.3. https://data.inpi.fr/brevets/WO2020064749

2019. E. Traiffort, M. Schumacher. US Patent PCT/IB2019/050198: Treatment of demyelinating diseases. https://patentscope.wipo.int/search/en/detail.jsf?docId=SG306156278&_cid=P20-LHRP3C-67828-1

2019. P. Bougneres (Adrenas Therapeutics), G Gao. Adeno-associated virus gene therapy for 21-Hydroxylase. WO2019143803. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019143803&_cid=P20-LHRNJ8-31186-2

2018. R. Sitruk-Ware, M. Schumacher, A. Ghoumari. Patent US 10052335B2. Neuroprotection and myelin repair using Nestorone

2016. R. Sitruk-Ware, M. Schumacher, A. Ghoumari. US Patent 9,364,488 B2. The remyelination of axons is promoted by the synthetic testosterone analogue 7α-methyl-19-nortestosterone (MENT) (Patent:, June 14, 2016).

2015. H M Puccio, P Aubourg, R. G. Crystal, P. Bougneres. Methods and pharmaceutical compositions for the treatment and the prevention of cardiomyopathy due to Friedreich ataxia. US20150313969. https://patentscope.wipo.int/search/en/detail.jsf?docId=US152963691&_cid=P20-LHRNJ8-31186-3

2011. E.E. Baulieu, B. Chambraud. European patent EP 3 139 174 B1. FKBP52-TAU interaction as a novel therapeutic target for treating the neurological disorders involving TAU dysfunction.